Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | GAK | O14976 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | STK10 | O94804 | 1/20 | 0.35 |
| ▸ | CARS1 | P49589 | 1/20 | 0.35 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.35 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.35 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14937573 | 0.85 | TSHR (0.42) | EGFRTSHRNPC1ALDH1A1RAB9A | |
| SCHEMBL361802 | 0.84 | EGFR (0.47) | EGFRBRAFKITGAKRIPK2 | |
| SCHEMBL14937611 | 0.79 | EGFR (0.57) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL12503386 | 0.78 | MET (0.48) | EGFRTSHRBRAFNPC1ALDH1A1 | |
| SCHEMBL12503365 | 0.73 | MET (0.46) | EGFRTSHRBRAFKITRIPK2 | |
| SCHEMBL14937427 | 0.73 | TSHR (0.42) | EGFRTSHRBRAFNPC1RAB9A | |
| SCHEMBL10133801 | 0.71 | MET (0.46) | EGFRBRAFKIT | |
| SCHEMBL18040358 | 0.70 | MET (0.48) | EGFRBRAFALDH1A1KIT | |
| SCHEMBL14966643 | 0.69 | MET (0.47) | TSHRKIT | |
| SCHEMBL362781 | 0.68 | PLK4 (0.42) | EGFRGAKRIPK2BUB1STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593462-B1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS C-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO LTD (CN) | 2016-09-07 | — | — | EP | claimed |
| US-9242991-B2 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-26 | — | — | US | claimed |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2013-05-16 | — | — | US | claimed |
| US-9242991-B2 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| EP-2593462-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | Zhejiang Beta Pharma Inc. (CN) | 2013-05-22 | — | — | EP | disclosed |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
| WO-2012006960-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | ZHEJIANG BETA PHARMA INC. (CN) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | MET, RET, ABL1 | EGFR 30/4885TSHR 2399/4885BRAF 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.